Evidence map›Paper›PMID 34515085›Full record

SynthesisDermatology (Basel, Switzerland)2022

Impact of Pregnancy on Hidradenitis Suppurativa Disease Course: A Systematic Review and Meta-Analysis.

Justine R Seivright, Natalie M Villa, Tristan Grogan, Ram K Parvataneni, Alyssa M Thompson, Vivian Y Shi, Jennifer L Hsiao

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Dermatology (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Guideline
  2. Australasian hidradenitis suppurativa management guidelines.The Australasian journal of dermatology · 2025
    Guideline
  3. Guideline
  4. The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review.International journal of molecular sciences · 2022
    Pooled it
  5. Review
  6. Review
  7. Cumulative life course impairment: Evidence for hidradenitis suppurativa.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Justine R SeivrightDavid Geffen School of Medicine, University of California, Los Angeles, California, USA.
Natalie M VillaDepartment of Medicine, Division of Dermatology, University of California Los Angeles, Los Angeles, California, USA.
Tristan GroganDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Ram K ParvataneniDepartment of Obstetrics and Gynecology, University of California, Los Angeles, California, USA.
Alyssa M ThompsonUniversity of Arizona College of Medicine, Tucson, Arizona, USA.
Vivian Y ShiDepartment of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Jennifer L HsiaoDepartment of Medicine, Division of Dermatology, University of California Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · USUniversity of Arizona · USUniversity of Arkansas for Medical Sciences · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
NCATS NIH HHS UL1 TR001881
6 · The paper itself

Abstract

backgroundHormones are thought to play a role in hidradenitis suppurativa (HS). However, data on the HS disease course during pregnancy and the postpartum period has not been well established. The objective of this study is to analyze the available literature to determine HS disease activity during pregnancy and the postpartum period.

methodsThe PubMed and Embase databases were systematically searched for relevant articles from database inception until November 22, 2020. The inclusion criteria were a study population with the diagnosis of HS and discussion of pregnancy impact on the HS disease course or postpartum flare. Study characteristics, patient demographics, HS severity, and HS disease course during pregnancy and the postpartum period were extracted by 2 independent reviewers. The quality of included studies was assessed using the Newcastle-Ottawa Scale for observational studies. Heterogeneity was assessed using Cochran's Q statistic and I2 index. The random-effects meta-analytical model was used. The primary study outcome was the pooled odds ratio of improvement or of worsening of HS disease activity during pregnancy.

resultsThe systematic search identified 8 studies for analysis. There was a total of 672 cases for which data on the patient-reported HS disease course during pregnancy were available, and 164 cases for which data on patient-reported postpartum flare were available. In the meta-analyses, the rate of HS disease improvement was 24% (95% CI 0.13-0.40) and the rate of HS disease worsening was 20% (95% CI 0.11-0.34). Sixty percent (99/164) of patients experienced a postpartum flare.

conclusionWhile about a quarter of women will experience an improvement in HS during pregnancy, the majority will have a stable or worsened disease course, and over half of patients will experience a postpartum flare. Close monitoring of HS patients is needed during pregnancy and postpartum periods, as patients may need continued, or even escalated, disease management.

Indexed as

Hidradenitis SuppurativaDisease ProgressionFemaleHumansOdds RatioPregnancyAcne inversaDisease courseHidradenitis suppurativaPostpartum flarePregnancy

Identifiers

PMID34515085
PMCPMC8850527
OpenAlexW3194095060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.